Polyrizon Ltd. (PLRZ)
| Market Cap | 3.06M |
| Revenue (ttm) | n/a |
| Net Income (ttm) | -1.07M |
| Shares Out | 3.24M |
| EPS (ttm) | -0.42 |
| PE Ratio | n/a |
| Forward PE | n/a |
| Dividend | n/a |
| Ex-Dividend Date | n/a |
| Volume | 13,785 |
| Open | 1.000 |
| Previous Close | 0.980 |
| Day's Range | 0.933 - 1.000 |
| 52-Week Range | 0.770 - 1.970 |
| Beta | n/a |
| Analysts | n/a |
| Price Target | n/a |
| Earnings Date | Nov 29, 2024 |
About PLRZ
Polyrizon Ltd., a biotech company, engages in the development of medical device hydrogels in the form of nasal sprays in Israel. The company uses its proprietary technology to develop its products comprising Capture and Contain, a containment barrier against a range of allergen particulates and viruses; and Trap and Target for nasal delivery of active pharmaceutical ingredients. It develops PL-14, a nasal allergies blocker; PL-15 for COVID-19; and PL-16 for influenza. The company was incorporated in 2005 is headquartered in Ra'anana, Israel. [Read more]
Financial Performance
Financial StatementsNews
Aegis Capital Corp. Acted as Sole Bookrunner on a $4.2 Million (IPO) Initial Public Offering for Polyrizon Ltd. (NASDAQ: PLRZ)
NEW YORK, NY / ACCESSWIRE / October 30, 2024 / Aegis Capital Corp. acted as Sole Bookrunner on a $4.2 Million (IPO) Initial Public Offering for Polyrizon Ltd. (NASDAQ:PLRZ).
Polyrizon Announces Closing of $4.2 Million Initial Public Offering
Raanana, Israel, Oct. 30, 2024 (GLOBE NEWSWIRE) -- Polyrizon Ltd. (the "Company" or "PLRZ"), a development stage biotech company specializing in the development of innovative medical device hydrogels,...
Polyrizon Announces Pricing of $4.2 Million Initial Public Offering and Listing on the Nasdaq Capital Market Under New Ticker “PLRZ”
Raanana, Israel, Oct. 28, 2024 (GLOBE NEWSWIRE) -- Polyrizon Ltd. (the "Company" or "PLRZ"), a development stage biotech company specializing in the development of innovative medical device hydrogels,...
Polyrizon IPO Registration Document (F-1)
Polyrizon has filed to go public with an IPO on the NASDAQ.